Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases

Acta Oncologica

Volumn 52, Issue 5, 2013, Pages 994-1001

  Adam, Zdeněk ^a   Szturz, Petr ^a   Vaníček, Jiří ^b,c   Moulis, Mojmír ^a   Pour, Luděk ^a   Krejčí, Marta ^a   Hájek, Roman ^a   Mayer, Jiří ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; METHYLPREDNISOLONE; PSORALEN; ETOPOSIDE; FILGRASTIM; HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; LANGERHANS CELL HISTIOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; ULTRAVIOLET A RADIATION; CANCER CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HORMONE SUBSTITUTION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOPENIA; MIDDLE AGED; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PHOTOCHEMOTHERAPY; RADIATION DOSE; SKIN DEFECT; SYSTEMIC THERAPY; THROMBOCYTE COUNT; TONSILLITIS; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CLADRIBINE; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84877358174     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.716164     Document Type: Article

References (29)

1. Egeler R M , D 'Angio G J . L angerhans cell histiocytosis. J Pediatr 1995; 127: 1-11 .
2. Weitzman S , W ayne A S , A rceci R , L ipton JM , W hitlock JA . Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the histiocyte society and review of the literature . Med Pediatr Oncol 1999; 33: 476-81 .
3. Ladisch S , G adner H . T reatment of Langerhans cell histiocytosis-evolution and current approaches . Br J Cancer Suppl 1994; 23: S41-6 .
4. Satter EK, H igh WA . L angerhans cell histiocytosis: A review of the current recommendations of the Histiocyte Society . Pediatr Dermatol 2008; 25: 291-5 .
5. Baumgartner I , v on Hochstetter A , B aumert B, L uetolf U , Follath F . Langerhans '-cell histiocytosis in adults . Med Pediatr Oncol 1997; 28: 9-14 .
6. Aric ò M , G irschikofsky M , G é n é reau T , K lersy C, M cClain K , Grois N , et al . Langerhans cell histiocytosis in adults . Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39: 2341-8 .
7. Stockschlaeder M , S ucker C . A dult Langerhans cell histiocytosis . Eur J Haematol 2006; 76: 363-8 .
8. McClain K , A llen C , E brahim S . R eview of histiocytosis treatment and neurotoxicity in adult patients (abstract) . Pediatr Blood Cancer 2009; 53: 696 .
9. Gulliford M C , C harlton J , L atinovic R . R isk of diabetes associated with prescribed glucocorticoids in a large population . Diabetes Care 2006; 29: 2728-9 .
10. Histiocyte Society Evaluation and Treatment Guidelines. Available from: http://www.hematologie-amc.nl/odijk/bijlagennietinDBS/ SocietyLCHTreatmentGuidelines.pdf. [cited 2012 April 3]
11. Kassner E . E valuation and treatment of chemotherapy extravasation injuries . J Pediatr Oncol Nurs 2000; 17: 135-48 .
12. Saven A , F igueroa M L , P iro L D , R osenblatt J D . 2-Chlorodeoxyadenosine to treat refractory histiocytosis X . N Engl J Med 1993; 329: 734-5 .
13. Dimopoulos MA , T heodorakis M , K ostis E, P apadimitris C, Moulopoulos LA , Anastasiou-Nana M . Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine . Leuk Lymphoma 1997; 25: 187-9 .
14. Weitzman S , B raier J, D onadieu J, E geler RM , G rois N, Ladisch S , et al . 2 '-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH) . Results of the LCH-S-98 protocol of the Histiocyte Society . Pediatr Blood Cancer 2009;53:1271-6.
15. Saven A , B urian C . C ladribine activity in adult Langerhanscell histiocytosis . Blood 1999; 93: 4125-30 .
16. Grau J , R ibera JM , T ormo M , I ndiano JM , V ercher J , S andoval V , et al . Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis . Study of 9 patients . Med Clin (Barc) 2001;116:339-42. [Spanish].
17. Pardanani A , P hyliky RL , L i CY , T efferi A . 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis . Mayo Clin Proc 2003; 78: 301-6 .
18. Stine K C, S aylors R L , W illiams L L, B ecton D L . 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients . Med Pediatr Oncol 1997; 29: 288-92 .
19. Szturz P , A dam Z, R eh ák Z, K oukalová R , S laisov á R , Stehl í kov á O , et al . Lenalidomide proved effective in multisystem Langerhans cell histiocytosis . Acta Oncol 2012; 51: 412-5 .
20. Carrera CJ, T erai C, L otz M , C urd JG , P iro LD , B eutler E , et al . Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo . A novel approach to immunosuppressive therapy. J Clin Invest 1990; 86: 1480-8 .
21. Liliemark J . T he clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32: 120-31 .
22. Bryson HM , S orkin EM . C ladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993; 46: 872-94 .
23. Liliemark J, A lbertioni F , H assan M , J uliusson G . O n the bioavailability of oral and subcutaneous 2-chloro-2 '-deoxyadenosine in humans: Alternative routes of administration . J Clin Oncol 1992; 10: 1514-8 .
24. Montella L , I nsabato L , P almieri G . I matinib mesylate for cerebral Langerhans '-cell histiocytosis . N Engl J Med 2004; 351: 1034-5 .
25. Baumann M , C erny T , S ommacal A , K oeberle D . Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib . Hematol Oncol 2012; 30: 101-4 .
26. Cheson BD . N ew prospects in the treatment of indolent lymphomas with purine analogues . Cancer J Sci Am 1998; 4(Suppl 2): S27-36 .
27. Robak T , K ordek R , R obak E, B artkowiak J, B iernat W, Liberski P , et al . Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: A clonal disease responding to treatment with cladribine, and cyclophosphamide . Leuk Lymph 2002; 43: 2041-6 .
28. Felix C A . C hemotherapy-related second cancers. In: Neugut AI, Meadows AT, Robinson E, editors. Multiple primary cancers. Philadelphia (PA): Lippincott Williams and Wilkins; 1999.
29. Ottaviano F , F inlay JL . D iabetes insipidus and Langerhans cell histiocytosis: A case report of reversibility with 2-chlorodeoxyadenosine . J Pediatr Hematol Oncol 2003; 25: 575-7 .